Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3896MR)

This product GTTS-WQ3896MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Chimeric
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3896MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15704MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ3092MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA APG-101
GTTS-WQ15476MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA UCB-0107
GTTS-WQ7922MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GSK3196165
GTTS-WQ14295MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ7949MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ10215MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ4943MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA c13C6-FR1-N
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW